Vext Strengthens Balance Sheet and Sharpens Focus on Core Markets with Strategic Sale of Kentucky Medical Processing License
Vext Science (VEXTF) has announced the strategic sale of its Kentucky medical cannabis processing license for US$880,000 through its subsidiary Vapen Kentucky. The transaction aligns with the company's focused approach on its core markets in Arizona and Ohio.
Prior to the sale, on March 16, 2025, Vext acquired the remaining 50% membership interest in Vapen Kentucky from its joint venture partner using non-cash consideration. Following the transaction's closure, Vapen Kentucky will redirect its focus to hemp-related business opportunities.
The proceeds will be allocated towards:
- Repayment of existing credit facilities
- Development of Ohio retail footprint
- General corporate purposes
Vext Science (VEXTF) ha annunciato la vendita strategica della sua licenza di lavorazione della cannabis medica del Kentucky per US$880.000 tramite la sua controllata Vapen Kentucky. La transazione è in linea con l'approccio focalizzato dell'azienda sui suoi mercati principali in Arizona e Ohio.
Prima della vendita, il 16 marzo 2025, Vext ha acquisito il restante 50% di partecipazione in Vapen Kentucky dal suo partner in joint venture utilizzando un corrispettivo non monetario. Al termine della transazione, Vapen Kentucky reindirizzerà il suo focus verso opportunità di business legate alla canapa.
I proventi saranno destinati a:
- Rimborso delle linee di credito esistenti
- Sviluppo della presenza al dettaglio in Ohio
- Scopi aziendali generali
Vext Science (VEXTF) ha anunciado la venta estratégica de su licencia de procesamiento de cannabis médica en Kentucky por US$880,000 a través de su subsidiaria Vapen Kentucky. La transacción se alinea con el enfoque centrado de la empresa en sus mercados clave en Arizona y Ohio.
Antes de la venta, el 16 de marzo de 2025, Vext adquirió el 50% restante de la participación en Vapen Kentucky de su socio de joint venture utilizando una contraprestación no monetaria. Tras el cierre de la transacción, Vapen Kentucky redirigirá su enfoque hacia oportunidades de negocio relacionadas con el cáñamo.
Los ingresos se destinarán a:
- Reembolso de las líneas de crédito existentes
- Desarrollo de la presencia minorista en Ohio
- Propósitos corporativos generales
Vext Science (VEXTF)는 자회사 Vapen Kentucky를 통해 켄터키의 의료용 대마초 가공 라이센스를 US$880,000에 전략적으로 판매한다고 발표했습니다. 이 거래는 애리조나와 오하이오의 핵심 시장에 집중하는 회사의 접근 방식과 일치합니다.
판매 이전인 2025년 3월 16일, Vext는 공동 투자 파트너로부터 Vapen Kentucky의 남은 50% 지분을 비현금 대가로 인수했습니다. 거래가 완료된 후, Vapen Kentucky는 대마 관련 비즈니스 기회로 초점을 전환할 것입니다.
수익은 다음과 같이 배분됩니다:
- 기존 신용 시설 상환
- 오하이오 소매 공간 개발
- 일반 기업 목적
Vext Science (VEXTF) a annoncé la vente stratégique de sa licence de transformation de cannabis médical du Kentucky pour US$880,000 par l'intermédiaire de sa filiale Vapen Kentucky. La transaction s'inscrit dans l'approche ciblée de l'entreprise sur ses marchés clés en Arizona et Ohio.
Avant la vente, le 16 mars 2025, Vext a acquis le reste des 50% d'intérêts de membre dans Vapen Kentucky auprès de son partenaire de coentreprise en utilisant une contrepartie non monétaire. Après la clôture de la transaction, Vapen Kentucky redirigera son attention vers des opportunités commerciales liées au chanvre.
Les produits seront alloués à :
- Remboursement des facilités de crédit existantes
- Développement de la présence au détail en Ohio
- Objectifs d'entreprise généraux
Vext Science (VEXTF) hat den strategischen Verkauf seiner medizinischen Cannabisverarbeitungs-Lizenz in Kentucky für US$880.000 über seine Tochtergesellschaft Vapen Kentucky angekündigt. Die Transaktion steht im Einklang mit dem fokussierten Ansatz des Unternehmens auf seine Kernmärkte in Arizona und Ohio.
Vor dem Verkauf erwarb Vext am 16. März 2025 die verbleibenden 50% der Mitgliedschaftsanteile an Vapen Kentucky von seinem Joint-Venture-Partner unter Verwendung einer nicht monetären Gegenleistung. Nach Abschluss der Transaktion wird Vapen Kentucky seinen Fokus auf geschäftliche Möglichkeiten im Bereich Hanf umleiten.
Die Erlöse werden verwendet für:
- Rückzahlung bestehender Kreditfazilitäten
- Entwicklung der Einzelhandelspräsenz in Ohio
- Allgemeine Unternehmenszwecke
- Strategic sale of Kentucky license generates US$880,000 in cash proceeds
- Strengthening of balance sheet through debt reduction
- Increased focus on core profitable markets (Arizona and Ohio)
- Investment in Ohio retail footprint expansion
- Exit from Kentucky's medical cannabis processing market
- Reduction in market diversification
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2025) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company"), a U.S.-based cannabis operator with vertically integrated operations in Arizona and Ohio, today announced that Vapen Kentucky, LLC ("Vapen Kentucky"), a wholly owned subsidiary of Vext, together with its local partner, has entered into a definitive agreement (the "Sale Agreement") to sell a medical cannabis processing license in the state of Kentucky for gross proceeds to the Company of US
"This transaction underscores our disciplined approach to capital allocation and strategic focus on maximising returns in our core markets," said Eric Offenberger, CEO of Vext. "By divesting the processing license in Kentucky, we are deepening our focus on our core operations in Arizona and Ohio, where we see the most compelling opportunities to drive long-term value. The proceeds of the sale strengthens our balance sheet and will support the build out of our Ohio retail footprint as we continue to prioritize profitability and cash flow growth across our vertically-integrated operations."
On March 16, 2025, Vext acquired the remaining
Terms of the Transaction
Vapen Kentucky will receive US
The Transaction remains subject to customary closing conditions, including regulatory approval by the state of Kentucky. Vext expects the Transaction to close during the second quarter of 2025.
For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com.
About Vext Science, Inc.
Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio. Vext's expertise spans from cultivation through to retail operations in its key markets. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value.
Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.
For more details on the Vapen brand:
Vapen website: VapenBrands.com
Instagram: @vapen
Facebook: @vapenbrands
Forward Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements related to the Transaction, including the receipt of regulatory approvals, the anticipated closing date and use of proceeds, and other statements regarding future developments and the business and operations of Vext, including the transition of Vapen Kentucky to focus on hemp opportunities and the Company's anticipated results from operations, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at www.sedarplus.ca.
Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change.
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
Eric Offenberger
Chief Executive Officer
844-211-3725
For further information:
Jonathan Ross, Vext Investor Relations
jon.ross@loderockadvisors.com
416-244-9851
SOURCE: Vext Science, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247325
FAQ
How much is Vext Science (VEXTF) selling its Kentucky medical cannabis processing license for?
When will Vext Science (VEXTF) complete the sale of its Kentucky license?
How will Vext Science (VEXTF) use the proceeds from the Kentucky license sale?
What markets will Vext Science (VEXTF) focus on after selling the Kentucky license?
What will happen to Vapen Kentucky after the license sale?
